Please assess the completion status of the following clinical trial:

Trial Title: Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children \>6 years of age and \< 12 years of age, who snore and have an apnea hypopnea index (AHI) \< or equal 7 or Respiratory arousal index \> or equal 2~Exclusion Criteria:~* Hypersensitivity to budesonide~* Recent nasal trauma~* Nasal surgery or nasal septum perforation~* Current therapy with drugs interacting with budesonide (erythromycin clarythromycin, ketoconazole and cimetidine)~* Immunodeficiency or immunosuppressant therapy~* Craniofacial, neuromuscular, syndromic or defined genetic abnormalities~* Acute upper respiratory tract infection~* Systemic corticosteroid therapy or antibiotic therapy in the 2 weeks previous to the study, and~* Children who already had adenotonsillectomy in the past 12 months.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): Budesonide for 6 weeks followed by crossover to placebo
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 6 weeks followed by crossover to treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).